Aligos Therapeutics, Inc. (ALGS) Return on equity 2020–2025
Aligos Therapeutics, Inc. (ALGS) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-45.2%FY2025 · since FY2020: -49.3% → -45.2%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -45.2% | — |
| FY2023 | -95.2% | -2.8 pp |
| FY2022 | -92.4% | -23.0 pp |
| FY2021 | -69.5% | -20.1 pp |
| FY2020 | -49.3% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More ALGS financial trends
ALGS RevenueALGS Net incomeALGS Net marginALGS Gross profitALGS Gross marginALGS Operating incomeALGS Operating marginALGS Operating cash flowALGS Free cash flowALGS Capital expendituresALGS Stock buybacksALGS Dividends paidALGS Total assetsALGS Total liabilitiesALGS Shareholders’ equityALGS overview →